Navigation Links
Cardica Announces Fiscal 2009 Second Quarter Financial Results

REDWOOD CITY, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Cardica, Inc. (Nasdaq: CRDC) today reported financial results and corporate progress for its fiscal 2009 second quarter and six months ended December 31, 2008.

"Clinical adoption of our PAS-Port(R) Proximal Anastomosis System by cardiothoracic surgeons for use in coronary artery bypass graft (CABG) procedures since FDA clearance in September has been encouraging," said Bernard A. Hausen, M.D., Ph.D., president and chief executive officer of Cardica. "During the quarter, nearly 200 surgeons were trained to use the PAS- Port system. The PAS-Port system has been used in increasing numbers of CABG surgeries throughout the United States, including in dozens of total connector CABG cases, in which our C-Port and PAS-Port automated systems are used to connect all bypass vein grafts, eliminating the need to hand sew these vessels."

Recent Highlights and Accomplishments

-- Trained a total of 226 U.S. surgeons on the PAS-Port system since U.S. Food and Drug Administration clearance, including 196 in the fiscal 2009 second quarter alone, and a total of 384 surgeons on the C-Port(R) Distal Anastomosis Systems since product introduction;

-- Increased cumulative worldwide shipments of PAS-Port systems to over 11,500 units, with 1,827 units shipped in the fiscal 2009 second quarter; the majority of units were shipped to U.S. customers;

-- Increased cumulative worldwide shipments of C-Port systems to over 8,000 units, with 993 units shipped in the fiscal 2009 second quarter;

-- Enabled cardiothoracic surgeons to perform dozens of total connector coronary artery bypass, or C-CAB(TM), procedures for the first time in the United States, using only the C-Port and PAS-Port systems to attach bypass grafts;

-- On January 7, 2009, ORLive hosted a webcast of a robot-assisted, closed-chest CABG procedure performed by internationally renowned cardiothoracic surgeon Sudhir Srivastava, M.D., of the University of Chicago Medical Center, using Cardica's C-Port Flex-A system.

Fiscal 2009 Second Quarter and Six Months Ended December 31, 2008, Financial Results

Total net revenue was approximately $2.9 million for the fiscal 2009 second quarter compared with $1.7 million for the fiscal 2008 second quarter. Total product sales were approximately $2.0 million for the fiscal 2009 second quarter, compared with $1.3 million for the same period of fiscal 2008. Cost of product sales was approximately $1.5 million for the fiscal 2009 second quarter, representing a 27 percent product gross margin, compared with $1.2 million for the fiscal 2008 second quarter.

Research and development expenses were approximately $2.1 million for the fiscal 2009 second quarter compared with $1.7 million for the fiscal 2008 second quarter. Selling, general and administrative expenses for the fiscal 2009 second quarter were approximately $4.1 million compared with $3.2 million for the fiscal 2008 second quarter.

The net loss for the fiscal 2009 second quarter was approximately $4.7 million, or $0.30 per share, compared with a net loss of approximately $4.2 million, or $0.29 per share, for the fiscal 2008 second quarter.

Total net revenue for the six months ended December 31, 2008, was approximately $5.1 million compared with approximately $3.0 million for the same period of fiscal 2008. Total operating costs and expenses for the six months ended December 31, 2008, were approximately $15.0 million compared with approximately $11.4 million for the same period of fiscal 2008. The net loss for the first six months of fiscal 2009 was approximately $9.9 million, or $0.63 per share, compared with a net loss of approximately $7.8 million, or $0.56 per share, for the same period of fiscal 2008.

Cash and investments at December 31, 2008, were $13.1 million, compared with $17.6 million at September 30, 2008, and $23.3 million at June 30, 2008. As of December 31, 2008, there were approximately 15.8 million shares of common stock outstanding.

Financial Guidance for Fiscal 2009

"We are pleased with surgeon adoption of our PAS-Port system to date, and this quarter proved to be one of our best ever in terms of opening new hospital accounts. However, acceptance of new technology by hospitals is hard to predict," said Bob Newell, vice president, finance and chief financial officer of Cardica. "In this financing environment, we have pushed out to a later date the date by when we will need additional cash by reducing our expenses, headcount and planned spending."

It is still early in the adoption of Cardica's systems and regular consistent usage patterns are difficult to predict. Cardica expects revenue from both its PAS-Port and C-Port product lines to grow quarter over quarter. However, because accurately forecasting product revenue for new and recently introduced products in the current economic environment is difficult, Cardica has determined not to provide product revenue guidance for fiscal 2009. Development revenue from corporate collaborations for fiscal 2009 is expected to be between $2 million and $3 million.

On January 7, 2009, Cardica announced an initiative to reduce costs by eliminating approximately 13 positions. Cardica anticipates that the cost savings from the workforce reduction initiative will be approximately $3 million annually. In addition, Cardica has taken other steps to reduce expenses and conserve cash. Cardica estimates that the total cash expenses to be incurred in connection with the workforce reduction will be approximately $200,000, the majority of which will be incurred in the third fiscal quarter of 2009. Accordingly, Cardica believes that fiscal 2009 research and development, sales, general and administrative expenses will total between $23 and $24 million, including non-cash stock-based compensation expense of approximately $2 million.

Conference Call Details

Cardica's management will host a conference call to discuss Cardica's financial results and provide an update on Cardica's business. To access the live conference call on January 29, 2009, at 4:30 p.m. Eastern Time via phone, please dial 800-322-5044 from the United States and Canada or 617-614-4927 internationally. The conference ID is 16291196. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through February 5, 2009, and may be accessed by dialing 888-286-8010 from the United States and Canada or 617-801-6888 internationally. The replay passcode is 32762148.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of Cardica's website at Please connect to the website at least 15 minutes prior to the call to allow for any necessary software downloads.

About Cardica

Cardica is a leading provider of automated anastomosis systems for coronary artery bypass graft (CABG) surgery. By replacing hand-sewn sutures with easy-to-use automated systems, Cardica's products provide cardiovascular surgeons with rapid, reliable and consistently reproducible anastomoses, or connections of blood vessels, often considered the most critical aspect of the CABG procedure. Cardica's C-Port(R) Distal Anastomosis Systems are marketed in the United States and Europe and its PAS-Port(R) Proximal Anastomosis System is marketed in the United States, Europe and Japan. Cardica also is developing additional devices with Cook Medical to facilitate vascular closure and other surgical procedures.

Forward-Looking Statements

This press release contains "forward-looking" statements, including the matters described under the heading "Financial Guidance for Fiscal 2009." Any statements contained in this press release that are not historical facts may be deemed to be forward-looking statements. The words "anticipates" "will," "expect," "believe" and similar expressions are intended to identify forward- looking statements. There are a number of important factors that could cause Cardica's results to differ materially from those indicated by these forward- looking statements, including risks associated with Cardica's dependence upon the success of its current products, market acceptance of Cardica's C-Port Distal Anastomosis Systems and PAS-Port Proximal Anastomosis System, manufacturing of the C-Port Distal Anastomosis Systems and PAS-Port Proximal Anastomosis System and its suppliers, Cardica's sales, marketing and distribution strategy and capabilities, success of pre-clinical studies of and regulatory activities related to our collaborations, the impact of the workforce reduction on Cardica's business, unanticipated charges not currently contemplated that may occur as a result of the restructuring plan, Cardica's ability to execute on its strategy and general business and economic conditions and Cardica's need for additional funding, as well as other risks detailed from time to time in Cardica's SEC reports, including its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2008. Cardica does not undertake any obligation to update forward-looking statements. You are encouraged to read Cardica's reports filed with the U.S. Securities and Exchange Commission, available at

                       ~financial statements to follow~

                                Cardica, Inc.
                           Statements of Operations
               (amounts in thousands except per share amounts)

                                            Three months        Six months
                                               ended              ended
                                            December 31,        December 31,
                                          2008       2007     2008      2007
                                             (unaudited)        (unaudited)

      Product sales, net                  $1,995     $1,283   $3,555   $2,309
      Development revenue                    928        395    1,451      702
      Royalty revenue                         21         16       44       32
            Total revenue                  2,944      1,694    5,050    3,043

    Operating costs and expenses
      Cost of product sales                1,463      1,199    2,573    2,212
      Research and development             2,079      1,746    4,404    3,434
      Selling, general and
       administrative                      4,109      3,176    8,001    5,729
            Total operating costs and
             expenses                      7,651      6,121   14,978   11,375

    Loss from operations                  (4,707)    (4,427)  (9,928)  (8,332)
    Interest income                           43        283      141      553
    Interest expense                         (30)       (25)     (60)     (50)
    Other income (expense)                    (3)         2       (4)       3

    Net loss                             $(4,697)   $(4,167) $(9,851) $(7,826)

    Basic and diluted net loss per share  $(0.30)    $(0.29)  $(0.63)  $(0.56)

    Shares used in computing basic and
       diluted net loss per share         15,781     14,471   15,761   14,037

    Condensed Balance Sheets
    (amounts in thousands)                       December 31,        June 30,
                                                     2008              2008
    Assets                                        (unaudited)        (Note 1)
      Cash and investments                         $13,086           $23,265
      Other assets                                   5,842             4,985
          Total assets                             $18,928           $28,250

    Liabilities and stockholders' equity
      Total other current liabilities               $2,084            $3,348
      Deferred revenue                               2,007             1,485
      Total long-term liabilities                    2,000             2,000
      Stockholders' equity                          12,837            21,417
           Total liabilities and
            stockholders' equity                   $18,928           $28,250

    (1) Derived from audited financial statements

SOURCE Cardica, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cardica Announces Fiscal 2009 First Quarter Financial Results
2. Cardica Receives $1 Million Milestone Payment From Cook Medical for Development of Heart Defect Closure Device
3. Cardica to Present at Jefferies 2nd Annual Healthcare Conference
4. Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress
5. Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair
6. Cardica and Cook Sign Agreement to Expand Cook Vascular Closure Device Product Family
7. Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery
8. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Omnitura Therapeutics Announces Private Placement Financing
11. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... The Blavatnik Family Foundation and ... Finalists of the 2017 Blavatnik Regional Awards for Young Scientists. Established in ... by the New York Academy of Sciences to honor the excellence of outstanding ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality ... Several trends in analytical testing are being attributed to new regulatory requirements for ...
(Date:10/11/2017)... NJ (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic ... one eye at a time. So which eye do you rinse first if a dangerous ... have Plum Duo Eye Wash with its unique dual eye piece. , “Whether ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofilerâ„¢ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at  under "SEC ... . 2016 Year Highlights: Acquisition ...
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
Breaking Biology News(10 mins):